Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
23 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
WIEN
WIEN
COMET: A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late onset Pompe disease (AT)
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Endokrinologie und Stoffwechsel
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
COMET: A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of NeoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late onset Pompe disease -BE
Erasme Hospital - ULB
Centre de Référence Neuromusculaire Erasme-HUDERF
BELGIO
VLAAMS BRABANT
LEUVEN
An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease (phase II-III)- BE
UZ Leuven - Campus Gasthuisberg
UZ Leuven
FRANCIA
ILE-DE-FRANCE
PARIS
An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease (Phase II-III) - FR
Institut de Myologie - Hôpital Pitié-Salpêtrière
Unité clinique de pathologie neuromusculaire
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease (Phase II-III) - DE
Institution: Information not provided - DE
REGNO UNITO; GRAN BRETAGNA
Tyne & Wear
NEWCASTLE-UPON-TYNE
An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe DiseasE - GB
Newcastle University
Newcastle Clinical Trials Unit
SPAGNA
Andalucía
CÁDIZ
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Universitario Puerta del Mar
Unidad clínica de Neurología y Neurofisiología
SPAGNA
Cataluña
BARCELONA
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
SPAGNA
Cataluña
ESPLUGUES DE LLOBREGAT
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Sant Joan de Déu Barcelona
Servicio de Neurología
SPAGNA
Comunidad Valenciana
VALENCIA
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
SPAGNA
Madrid
MADRID
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatmentnaïve Patients with Late-onset Pompe Disease - ES
Hospital Universitario La Paz
Servicio de Neurología
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naïve Patients With Late-onset Pompe Disease - GB
Institution: Information not provided - US
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PROPEL Study: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease - AT
Institution: Information not provided - AT
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLYCO-1B: Evaluation of the Safety and Efficacy of Empagliflozin Administration as a Treatment for Neutropenia in Patients With Glycogenosis Type 1b and G6PC3 Deficiency
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGIO
VLAAMS BRABANT
LEUVEN
PROPEL Study: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo - BE
UZ Leuven - Campus Gasthuisberg
Dienst neurologie/ Department of Neurology
SPAGNA
Cataluña
BARCELONA
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen Storage Disease Type Ia (GSDIa) - ES
Institution: Information not provided - ES
STATI UNITI
North Carolina
DURHAM
A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy (Phase 1/2) - US
Duke University Medical Center
Division of Pediatrics-Medical Genetics
STATI UNITI
North Carolina
DURHAM
NEO-EXT: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease (Phase II - III) - US
Duke University Medical Center
Sperimentazioni cliniche internazionali
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5)
MRC Centre for Neuromuscular Diseases
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
COMET: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naïve Patients With Late-onset Pompe Disease
Institution: Information not provided - US
STATI UNITI
New Jersey
CRANBURY